Evaluation of 177Lu-PSMA-617 Therapy with STP Dosimetry Method in Patients with

Evaluation of 177Lu-PSMA-617 Therapy with STP Dosimetry Method in Patients with Metastatic Castration-Resistant Prostate Cancer


چاپ صفحه
پژوهان
صفحه نخست سامانه
نویسندگان
نویسندگان
اطلاعات تفضیلی
اطلاعات تفضیلی
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: سحر رضائی , اسماعیل قره پاپاق

عنوان کنگره / همایش: 2nd Tabriz Virtual Patient Safety and Medical Education International Congress (Tvpm) , Iran (Islamic Republic) , Tabriz , 2023

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله سحر رضائی
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه دانشکده پزشکی
کد مقاله 82871
عنوان فارسی مقاله Evaluation of 177Lu-PSMA-617 Therapy with STP Dosimetry Method in Patients with
عنوان لاتین مقاله Evaluation of 177Lu-PSMA-617 Therapy with STP Dosimetry Method in Patients with Metastatic Castration-Resistant Prostate Cancer
نوع ارائه پوستر
عنوان کنگره / همایش 2nd Tabriz Virtual Patient Safety and Medical Education International Congress (Tvpm)
نوع کنگره / همایش بین المللی
کشور محل برگزاری کنگره/ همایش Iran (Islamic Republic)
شهر محل برگزاری کنگره/ همایش Tabriz
سال انتشار/ ارائه شمسی 1402
سال انتشار/ارائه میلادی 2023
تاریخ شمسی شروع و خاتمه کنگره/همایش 1402/07/29 الی 1402/08/03
آدرس لینک مقاله/ همایش در شبکه اینترنت https://tabrizvpm.ir/about-us/
آدرس علمی (Affiliation) نویسنده متقاضی Department of Nuclear Medicine, Medical School, Tabriz University of Medical Sciences, Tabriz, Iran

نویسندگان
hide/show

نویسنده نفر چندم مقاله
سحر رضائیدوم
اسماعیل قره پاپاقاول

اطلاعات تفضیلی
hide/show

عنوان متن
خلاصه مقالهAim/Introduction: In metastatic castration-resistant prostate cancer (mCRPC), radiopharmaceutical therapies using Lutetium-177 prostate-specific membrane antigen (PSMA) ligands are showing promising results. Clinical trials have shown these radiopharmaceuticals to reduce prostate-specific antigen (PSA) levels and improve progression-free survival. Patient-specific activity personalization is currently impossible due to the lack of absorbed dose-effect relationships. This .makes it difficult to accurately calculate the amount of radiation needed to treat each patient Radiopharmaceutical therapies need dosimetry to be integrated into the standard workflow using (simplified imaging protocols such as single time point (STP rather than multi-time point (MTP). Our goal is to evaluate the differences between image-based dosimetry using STP and MTP for tumor treatment with 177Lu-PSMA-617 Method: A total of 20 patients with mCRPC had 177Lu-SPECT imaging data (24 hours, 36 hours, and 72 hours post-drug administration) available on the first 177Lu-PSMA-617 treatment cycle. Dosimetry was conducted using two different methods, the MTP method which incorporated images from all imaging time points, and the STP method. The STP method was used to assess dosimetry at a single time point. Tumors were delineated using the difference between Gaussian curves. Based on tumor density and coefficient of variation, support vector machines were used to classfy tumors. A receiver operating characteristic curve was generated to evaluate the model’s performance. The model was validated using an independent test set Results: The mean absorbed dose per time-integrated activity for tumors was 0.72 ± 0.12 (MTP method), 0.75 ± 0.12 (STP method 24h-image), 0.65 ± 0.13(STP method 36h-image) and 0.57 ± 0.12 (STP method 72h-image) Gy/GBq. There were no significant differences in the values of absorbed dose between various dosimetry methods Conclusion: Based on our results, we conclude that the STP method is reliable for measuring the amount of absorbed dose in tumors. Since normal tissue protection will be useful for improving cure rates and decreasing patient morbidity, STP can help to solve a key challenge in radiopharmaceutical therapies which is to receive maximum doses to cancer cells while minimizing damage to healthy tissue. This method can also be used to predict the efficacy of radiopharmaceutical therapies in mCRPC patients controlling tumor growth and preventing numerous side effects of multiple-course chemo-radiation therapies due to high doses of these methods. Additionally, .the STP method can be used to monitor the success of radiopharmaceutical therapies in cancer patients
کلمات کلیدیSingle Time Point Dosimetry; 177Lu-PSMA-617; mCRPC; radioligand therapy

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
Lu-PSMA.pdf1402/07/2969782دانلود
Tvpm.jpg1402/09/061265499دانلود